Background Lung cancer is one of the tumor types with highest incidence of thromboembolic
events (TE), especially adenocarcinoma subtype. ROS1 rearrangements confer higher risk …

Objectives: This study aimed to describe the longitudinal thromboembolism (TE) risk relative
to the natural history of disease and clinical course of ROS1 rearranged non-small cell lung …

Background Patients with cancer are at increased risk for venous thromboembolism (VTE),
and 8% to 15% of patients with advanced non–small-cell lung cancer (NSCLC) experience …

Introduction This study aims to determine whether advanced ROS1 gene-rearranged
NSCLC (ROS1+ NSCLC) has a higher than expected thromboembolic event (TEE) rate …

Background According to several studies, ROS1 rearrangement is associated with
thrombotic risk in non-small cell lung cancer (NSCLC). However, there is no clear …

Background The risk of thromboembolism (TE) is estimated to be 0.001% per year and
hereditary thrombophilia present in 0.2-5% of the general adult population. It is estimated …

Nonbacterial thrombotic endocarditis (NBTE) is a rare disease that most often found post
mortem. Malignant neoplasms, particularly adenocarcinomas, are the common underlying …

Introduction Based on the high incidence of thromboembolic events (TEs) observed in lung
adenocarcinomas with ALK translocations and taking into account the biological proximity of …

Introduction: Patients with cancer have higher risk of thrombosis compared to the general
population and particularly lung adenocarcinoma is considered at high risk for venous …

Disseminated intravascular coagulation (DIC) is a rare paraneoplastic complication in
advanced solid malignancies, with success of treatment and survival dependent on …